A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Phase 3

Completed

Conditions: Cushing's Syndrome

Interventions: Drug: mifepristone

Registration Number: NCT00569582

Lead Sponsor: Corcept Therapeutics

Brief Summary: Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.

Detailed Description: Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the adrenal glands is the subject of this protocol. Patients with exogenous Cushing's syndrome, which develops as a side effect of chronic administration of high doses of glucocorticoids, are not eligible for enrollment in this study.

This will evaluate the safety and efficacy of mifepristone for treatment of the signs and symptoms of hypercortisolemia in patients with endogenous Cushing's syndrome from ACTH-dependent or adrenal disorders.

The study will enroll subjects for whom the investigator has determined that medical treatment of endogenous hypercortisolemia is needed. Medical treatment may be intended to treat the effects of persistent or recurrent hypercortisolemia after surgery and/or radiation for Cushing's syndrome, to bridge the period of time for radiation to become effective, or when surgery is not feasible.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 50

Inclusion Criteria

Individuals eligible for enrollment into this study are adult male and non-pregnant female adult patients who:

Are at least 18 years of age
Have a confirmed diagnosis of endogenous hypercortisolemia caused by ACTH dependent or ACTH independent etiologies, including
1. Cushing's Disease (that has recurred after primary pituitary surgery, or has failed pituitary surgery, or has been treated with radiation therapy to the pituitary, or is not treatable with surgery, or exists in patients who are not candidates for surgery, and is confirmed by documentation of ACTH immuno-reactivity on a pathological evaluation of pituitary tissue from a previous surgical specimen or IPSS with a central-to-peripheral gradient (ratio) of >2 before or >3 after CRH administration).
2. Ectopic ACTH
3. Ectopic CRF secretion
4. Adrenal adenoma
5. Adrenal carcinoma
6. Adrenal autonomy
Require medical treatment of hypercortisolemia
Have diabetes mellitus type 2 or glucose intolerance AND/OR have hypertension *Note: To be eligible for inclusion subjects must have documented evidence of persistent endogenous hypercortisolemia

Exclusion Criteria

Individuals not eligible to be enrolled into the study are those who:

Have de novo Cushing's disease and are surgical candidates for pituitary surgery.
Have an acute or unstable medical problem, which could be aggravated by mifepristone treatment.
Taking medications within 14 days of the baseline visit (Day 1) that a) have a large first pass metabolism largely mediated by CYP3A4 and a narrow therapeutic margin and/or b) are strong CYP3A4 inhibitors.
Female patients of reproductive potential, who are pregnant or who are unable or unwilling to use medically acceptable, non-hormonal methods of contraception during the study.
Have received investigational treatment (drug, biological agent or device) within 30 days of Screening
Have a history of an allergic reaction or intolerance to CORLUX (mifepristone)
Have a non-endogenous source of hypercortisolemia such as factious hypercortisolemia (exogenous source of glucocorticoid, iatrogenic Cushing's syndrome), factious or therapeutic use of ACTH
Have Pseudo-Cushing's syndrome.
Receive PPARgamma agonist drugs (e.g. pioglitazone, rosiglitazone) within 4 months of Baseline (Day 1).
Postmenopausal women with an intact uterus who have experienced unexplained vaginal bleeding within 12 months of Screening are excluded.
Have renal failure as defined by a serum creatinine of ≥2.2 mg/dL.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	mifepristone	-

Primary Outcome Measures

Name	Time	Method
Improvement in Diabetes and/or Glucose Intolerance.	Baseline to Week 24	Responder is defined as subject with a decrease greater than or equal to 25% in area under the curve for glucose on 2-hour oral glucose test from baseline to week 24 or last visit, for Cushing's patients with type-2 diabetes mellitus/impaired glucose tolerance.
Decrease in Diastolic Blood Pressure.	Baseline to Week 24	Responder is defined as subject with a decrease greater than or equal to 5mm Hg in diastolic blood pressure from baseline to week 24 or last visit.

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (17): Sinai Hospital of Baltimore
🇺🇸
Baltimore, Maryland, United States
University of Mississippi Medical Center
🇺🇸
Jackson, Mississippi, United States
The Center for Diabetes and Endocrine Care
🇺🇸
Hollywood, Florida, United States
Northwestern University Feinberg Medical; Division of Endocrinology, Metabolism & Molecular Medicine
🇺🇸
Chicago, Illinois, United States
Stanford University Medical Center
🇺🇸
Stanford, California, United States
Cleveland Clinic Foundation; Dept of Endocrinology, Diabetes & Metabolism
🇺🇸
Cleveland, Ohio, United States
Endocrinology Center at North Hills, Froedtert and Medical College of Wisconsin
🇺🇸
Menomonee Falls, Wisconsin, United States
University of Texas Southwestern Medical Center
🇺🇸
Dallas, Texas, United States
AMCR Institute Inc.
🇺🇸
Escondido, California, United States
University of New Mexico HSC
🇺🇸
Albuquerque, New Mexico, United States
The University of Chicago
🇺🇸
Chicago, Illinois, United States
University of Alabama at Birmingham School of Medicine
🇺🇸
Birmingham, Alabama, United States
Massachusetts General Hospital
🇺🇸
Boston, Massachusetts, United States
University of Michigan Medical Center
🇺🇸
Ann Arbor, Michigan, United States
Oklahoma University Health Science Center
🇺🇸
Oklahoma City, Oklahoma, United States
Oregon Health Sciences University
🇺🇸
Portland, Oregon, United States
Diabetes and Glandular Disease Clinic
🇺🇸
San Antonio, Texas, United States